GETI.B

203

+0.3%↑

ATT

103.6

+2.37%↑

AMBEA

129.9

+2.85%↑

ARJOB

27.04

-1.24%↓

MSON.B

11.1

-2.2%↓

GETI.B

203

+0.3%↑

ATT

103.6

+2.37%↑

AMBEA

129.9

+2.85%↑

ARJOB

27.04

-1.24%↓

MSON.B

11.1

-2.2%↓

GETI.B

203

+0.3%↑

ATT

103.6

+2.37%↑

AMBEA

129.9

+2.85%↑

ARJOB

27.04

-1.24%↓

MSON.B

11.1

-2.2%↓

GETI.B

203

+0.3%↑

ATT

103.6

+2.37%↑

AMBEA

129.9

+2.85%↑

ARJOB

27.04

-1.24%↓

MSON.B

11.1

-2.2%↓

GETI.B

203

+0.3%↑

ATT

103.6

+2.37%↑

AMBEA

129.9

+2.85%↑

ARJOB

27.04

-1.24%↓

MSON.B

11.1

-2.2%↓

Inicio・Lista de Acciones・Vivesto AB

Vivesto AB

Cerrado

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave
By Trading Economics
Ingresos	2.3M -7.2M
BPA	-0.013
Empleados	4
EBITDA	-7.1M

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-27M 51M
Apertura anterior	0
Cierre anterior	0

Vivesto AB Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 feb 2026, 23:53 UTC

Acciones populares

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

1 mar 2026, 00:00 UTC

Noticias de Eventos Importantes

Trump's War on Iran Threatens to Drive Up Oil Prices and Inflation -- WSJ

28 feb 2026, 21:36 UTC

Ganancias

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 21:27 UTC

Noticias de Eventos Importantes

Iran Strikes Could Make Fed Rate Cuts Even Less Likely -- Barrons.com

28 feb 2026, 15:20 UTC

Ganancias

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 feb 2026, 14:43 UTC

Ganancias

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 14:40 UTC

Noticias de Eventos Importantes

What Defense Stocks Stand to Gain -- and Lose -- From the U.S. Attacks on Iran -- Barrons.com

28 feb 2026, 14:38 UTC

Ganancias

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 feb 2026, 13:51 UTC

Noticias de Eventos Importantes

What Defense Stocks Stand to Gain--and Lose--From the US Attacks on Iran -- Barrons.com

28 feb 2026, 13:47 UTC

Ganancias

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 13:44 UTC

Ganancias

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 feb 2026, 13:14 UTC

Ganancias

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 feb 2026, 12:41 UTC

Noticias de Eventos Importantes

Iran's Rulers Face an All-Out Battle for Survival -- Barrons.com

28 feb 2026, 10:30 UTC

Adquisiciones, fusiones, absorciones

All The Ways Netflix Actually Won Even Though It Lost Warner -- Heard on the Street -- WSJ

28 feb 2026, 02:32 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 feb 2026, 02:00 UTC

Adquisiciones, fusiones, absorciones

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 feb 2026, 02:00 UTC

Adquisiciones, fusiones, absorciones

Six Months, 9 Offers and $81 Billion. How -2-

28 feb 2026, 00:01 UTC

Adquisiciones, fusiones, absorciones

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 feb 2026, 23:46 UTC

Adquisiciones, fusiones, absorciones

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Adquisiciones, fusiones, absorciones

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Ganancias

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Ganancias

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Ganancias

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

Comparación entre iguales

Cambio de precio

Vivesto AB previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.